alectinib

11/11/2021 - "This evidence is the first to show that alectinib may be effective for this rare fusion type of non-small cell lung cancer, and these findings have important implications for drug selection in patients with this subtype. "
07/01/2023 - "The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? "
12/01/2022 - "Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort."
01/01/2019 - "Our results align with ALEX, confirming the clinical benefit of 600 mg of alectinib twice per day as a first-line treatment for ALK-positive non-small-cell lung cancer. "
01/01/2023 - "Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)."

11/01/2014 - "Alectinib showed potent efficacy against intracranial EML4-ALK-positive tumor. "
01/01/2022 - "Treatment with alectinib, an ALK inhibitor, led to a significant reduction in tumor size and calcification in the lymph nodes. "
08/01/2021 - "In addition, ALK rearrangements were detected by ALK (clone D5F3) immunohistochemical assay and fluorescence in situ hybridization (FISH), A final diagnosis of metastatic ALK-positive PASRF with polygonal cell morphology to the supraclavicular lymph node was made, and the patient was treated with Alectinib, which brought a reduction in tumor size and good results."
11/21/2020 - "Magnetic targeting efficiently enhanced the extravasation of alectinib-loaded nanoparticles from vessels into the tumor tissue, while the TAT targeting reactivated in the tumor tissue significantly improved the tumor cellular uptake of the nanocarrier. "
12/01/2014 - "Our results suggest that alectinib is effective against RET fusion-positive tumors. "

09/01/2017 - "Alectinib may be the best treatment for choroidal metastasis in patients harboring an ALK translocation because of its favorable side effect profile involving visual disturbances."
12/01/2022 - "For patients with measurable central nervous system (CNS) metastases, the CNS-ORR was 92.9% (95% CI: 66.1-99.8%), additionally, 80% (8/10) of patients experienced significant improvement in CNS-related symptoms following alectinib treatment. "
11/01/2016 - "Notably, one of these two patients had his dose of alectinib escalated to 900 mg twice daily and had clinical improvement in central nervous system metastases. "
11/01/2023 - "First-line alectinib treatment was effective for 2.5 years; however, liver metastases exacerbated. "
01/01/2019 - "However, the CNS efficacy of alectinib has not been established in patients with untreated symptomatic, large CNS metastases. "

01/01/2022 - "High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report."
01/01/2023 - "Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report."
01/01/2022 - "Here, we reported a patient with advanced lung adenocarcinoma harboring a SLC8A1-ALK fusion who benefited from first-line treatment with alectinib. "
11/11/2021 - "We report a rare EML4-ALK (E6;A18) fusion in a patient with lung adenocarcinoma that responded well to alectinib. "
11/01/2023 - "To date, neoadjuvant alectinib has only been reported in a few cases in locally advanced lung adenocarcinoma with ALK-rearranged. "

01/01/2019 - "The main aim of this review is to assemble on the efficacy of alectinib for the treatment of ALK+ NSCLC, to elaborate the activity of the drug in the central nervous system, and to debate on which is the position of this compound in the treatment course of ALK+ lung cancer patients."
05/01/2023 - "An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer."
01/01/2023 - "The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report."
12/01/2019 - "TTD in lung cancer symptoms was similar between treatment arms, despite longer duration of symptom improvement with alectinib; composite symptom endpoint (hazard ratio 1.10 [95% confidence interval: 0.72-1.68]). "
01/01/2017 - "An ALK inhibitor (alectinib) was administered, and the lung cancer lesions showed improvement. "